Renowned European biotech media “LABIOTECH.eu”, in collaboration with investors and analysts, has identified key trends shaping biotech development and compiled a list of Taiwan’s most noteworthy biotech companies for 2025. Among them, Senhwa Biosciences was highlighted for its pioneering work in developing first-in-class drugs distinguished by innovative mechanisms and substantial commercial potential. This recognition not only enhances Senhwa’s global visibility but also favorably positions it for licensing negotiations and commercialization opportunities.
In the feature article titled "Seven Biotech Companies Keeping Taiwan Dynamic in 2025," LABIOTECH notes that while Taiwan is globally recognized for its high-tech industries, particularly in electronics, the country has also strategically invested in developing a competitive biotech sector over the past two decades. Leveraging its robust capabilities in manufacturing, R&D, and data-driven innovation, Taiwan has successfully positioned itself as a regional biotech hub, focusing on precision medicine, immunotherapy, and new drug development.
The article emphasizes that although Taiwan may not yet compete directly with global biotech giants in the U.S. and Europe, strong government support and a dynamic research ecosystem have attracted foreign investment and fostered international collaborations. Among the seven highlighted biotech companies, Senhwa Biosciences stands out as the only company with a pipeline addressing oncology, rare diseases, and infectious diseases. It is also the only Taiwanese biotech firm selected for the U.S. national program, having secured clinical development sponsorships from both the National Cancer Institute’s (NCI) CTEP and NExT programs under the National Institutes of Health (NIH). Notably, its drug candidate Pidnarulex (CX-5461) has showed potential to convert cold tumors into hot tumors, contributing to enhanced responsiveness to immunotherapy. With clinical trials led by NIH, including a proposed immunotherapy combination study, Senhwa stands to benefit from its funding, expert resources, and regulatory networks, accelerating the drug’s path to market.
For the full article, please refer to
https://www.labiotech.eu/best-biotech/biotech-companies-taiwan/